Trial Search Results

Phase I Pilot Study to Evaluate the Prognostic Value of Perfusion CT for Primary Cervical Cancer

The investigators hope to learn whether perfusion CT is a useful way to assess primary cervical tumor microenvironment and whether there is a relationship between pretreatment perfusion CT measurements and primary cervical tumor size, lymph node involvement (as assessed by standard of care pretreatment fludeoxyglucose Positron emission tomography/CT (FDG-PET/CT)), and treatment response (as assessed by standard of care 3-month post-therapy FDG-PET/CT).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


Inclusion criteria:

   - >18 years old

   - with biopsy-proven squamous, adenocarcinoma or adenosquamous cervical cancer

   - no history of prior pelvic radiation and should be able to receive chemoradiation

   - non-pregnant women who have not previously undergone a hysterectomy, as that would
   have removed the cervix.

   - able to give informed consent

Exclusion criteria:

   - Subjects whose tumors are not FDG avid on the pre-therapy PET.

   - Allergy or inability to receive iodinated CT contrast

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Melissa Usoz